Cancer Research Audrey Hepburn  EMT and Cancer Progression and Treatment
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Osada, H.
Right arrow Articles by Takahashi, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Osada, H.
Right arrow Articles by Takahashi, T.
[Cancer Research 65, 10680-10685, December 1, 2005]
© 2005 American Association for Cancer Research


Priority Reports

ASH1 Gene Is a Specific Therapeutic Target for Lung Cancers with Neuroendocrine Features

Hirotaka Osada1, Yoshio Tatematsu1, Yasushi Yatabe2, Yoshitsugu Horio3 and Takashi Takahashi4

1 Division of Molecular Oncology, Aichi Cancer Center Research Institute; 2 Department of Pathology and Molecular Diagnostics; 3 Division of Respiratory Tract, Aichi Cancer Center Hospital; and 4 Division of Molecular Carcinogenesis, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan

Requests for reprints: Hirotaka Osada, Division of Molecular Oncology, Aichi Cancer Center Research Institute, 1-1 Kanokoden, Chikusa, Nagoya, 464-8681, Japan. Phone: 81-52-764-2993; Fax: 81-52-763-5233; E-mail: hosada{at}aichi-cc.jp.

Lung cancers with neuroendocrine features are usually aggressive, although the underlying molecular mechanisms largely remain to be determined. The basic helix-loop-helix protein, achaete-scute complex-like 1/achaete-scute homologue 1 (ASH1), is expressed in normal fetal pulmonary neuroendocrine cells and lung cancers with neuroendocrine elements and is suggested to be involved in lung carcinogenesis. In the present study, we show inhibition of ASH1 expression by plasmid-based RNA interference (RNAi) to significantly suppress growth of lung cancer cells with ASH1 expression through G2-M cell cycle arrest and accumulation of sub-G1 populations, possibly linked to cleavage of caspase-9 and caspase-7. However, lung cancer cell lines without ASH1 expression and immortalized normal BEAS2B bronchial epithelial cells were not affected. The RNAi-resistant mutant ASH1 clearly induced rescue from G2-M arrest, suggesting a target-specific effect of RNAi. An ASH1-RNAi adenovirus was also established and significantly inhibited not only in vitro cell proliferation but also in vivo xenograft growth of ASH1-positive NCI-H460 cells. Elevated levels of apoptosis were also observed in NCI-H460 xenografts with the ASH1-RNAi adenovirus. The present study therefore suggests that ASH1 plays a crucial role in lung cancer development and may be an effective therapeutic target in lung cancers with neuroendocrine features.




This article has been cited by other articles:


Home page
Endocr Relat CancerHome page
Y.-C. Wang, E. Gallego-Arteche, G. Iezza, X. Yuan, M. R Matli, S.-P. Choo, M. B Zuraek, R. Gogia, F. C Lynn, M. S German, et al.
Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors
Endocr. Relat. Cancer, March 1, 2009; 16(1): 267 - 279.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Jiang, B. J. Collins, N. Jin, D. N. Watkins, M. V. Brock, W. Matsui, B. D. Nelkin, and D. W. Ball
Achaete-Scute Complex Homologue 1 Regulates Tumor-Initiating Capacity in Human Small Cell Lung Cancer
Cancer Res., February 1, 2009; 69(3): 845 - 854.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
T. Yokoyama, H. Osada, H. Murakami, Y. Tatematsu, T. Taniguchi, Y. Kondo, Y. Yatabe, Y. Hasegawa, K. Shimokata, Y. Horio, et al.
YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation
Carcinogenesis, November 1, 2008; 29(11): 2139 - 2146.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Osada, S. Tomida, Y. Yatabe, Y. Tatematsu, T. Takeuchi, H. Murakami, Y. Kondo, Y. Sekido, and T. Takahashi
Roles of Achaete-Scute Homologue 1 in DKK1 and E-cadherin Repression and Neuroendocrine Differentiation in Lung Cancer
Cancer Res., March 15, 2008; 68(6): 1647 - 1655.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. Tanaka, K. Yanagisawa, K. Shinjo, A. Taguchi, K. Maeno, S. Tomida, Y. Shimada, H. Osada, T. Kosaka, H. Matsubara, et al.
Lineage-Specific Dependency of Lung Adenocarcinomas on the Lung Development Regulator TTF-1
Cancer Res., July 1, 2007; 67(13): 6007 - 6011.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. Kunnimalaiyaan and H. Chen
Tumor Suppressor Role of Notch-1 Signaling in Neuroendocrine Tumors
Oncologist, May 1, 2007; 12(5): 535 - 542.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.